Symptom Relief with Moderate Dose Chemotherapy in Lung Cancer
Author Information
Author(s): J.R. Hardy, T. Noble, I.E. Smith
Primary Institution: Royal Marsden Hospital
Hypothesis
Can moderate dose chemotherapy provide symptom relief in patients with advanced non-small cell lung cancer?
Conclusion
Moderate dose chemotherapy can lead to significant symptom relief in patients with advanced non-small cell lung cancer, despite a low objective response rate.
Supporting Evidence
- 75% of patients reported a complete disappearance or good improvement in at least one symptom.
- Only 21% of patients achieved an objective response.
- The overall symptomatic response rate was 67%.
- The median survival from start of treatment was 24 weeks.
Takeaway
This study shows that some patients with lung cancer felt better after receiving a specific type of chemotherapy, even if the cancer didn't shrink much.
Methodology
Patients received a combination of mitomycin-C, vinblastine, and cisplatin, and were assessed for symptom relief and objective response.
Potential Biases
The possibility of a placebo effect cannot be completely excluded.
Limitations
The median duration of symptomatic response was short-lived, at only 7 weeks.
Participant Demographics
24 patients (17 males, 7 females) with a median age of 53 years.
Want to read the original?
Access the complete publication on the publisher's website